2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
02:00 p.m. - 03:30 p.m.
MCCNO - La Nouvelle C
Chimeric Antigen Receptor T cell therapies have transformed the outcomes of patients with relapsed and refractory multiple myeloma and its role continues to expand at a rapid pace. This session brings together cutting edge data spanning novel approaches to improve the safety and efficacy of CAR-T products in the clinic. Presenters will explore how new strategies are changing the efficacy and safety balance to reshape treatment paradigms as the field pushes towards deeper and more durable responses. Attendees will get insights into latest clinical data in this important session.
Treatment Considerations, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Research, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult
PAPER

275 Efficacy and safety of sequenced BCMA-directed therapies in relapsed/refractory multiple myeloma – a retrospective, multicenter, international cohort study (SEQ-BCMA Study)

Christoph Schaefers, MD, Max Johannes Steinhardt, MD2, Emelie Skerbek, MD3, Ricardo Daniel Parrondo, MD4, Saurabh Chhabra, MD, MBBS5, Jan Frenking, MD6, Tim Richardson, MD7, Raphael Teipel, MD8, Maximilian Alexander Funk, MD, PhD9, Luise Fischer, PhD10, Paul Warncke11, Mathias Hänel, MD12, Christian Sebastian Michel, MD13, Maria Dampmann, MD14, Christopher M. M. Sauer, MD, PhD, MPH15, Lisa Marie Sgonina, MD16, Evgenii Shumilov I, MD17, Markus Maulhardt, MD18, Thomas Pabst, MD19, Normann Steiner20, Wolfgang Willenbacher, MD, PhD21, Michael Leisch22, Thomas Melchardt, MD23, Irene Strassl, MD24, Dominik Heim, MD25, Marie Harzer, MD26, Melinda Tan27, Andre De Menezes Silva Corraes, MD28, Lilan Gatti, MD29, David Böckle30, Stephan Bohl, MD31, Igor Wolfgang Blau, MD32, Jan Vorwerk33, Annamaria Brioli34, Caroline Cicin-Sain35, Sandra Sauer, MD36, Maximilian Al-Bazaz, MD37, Jule Cecilia Artzenroth, MD38, Leandra Bartke, MD39, Leon Cords, MD40, Abdulaziz Kamili, MD41, Ricardo Ahrens, MD42, Winfried Alsdorf, MD43, Christine Riedhammer44, Julia Mersi, MD45, Florian Eisele46, K. Martin Kortüm, MD47, Kai Rejeski, MD48, Sebastian Theurich, MD49, Christof Scheid, MD50, Marc-Steffen Steffen Raab, MD51, Carsten Bokemeyer, MD52, Hermann Einsele, MD, PhD53, Maximilian Merz, MD54, Saurabh Zanwar, MBBS, MD55, Prashant Kapoor, MD56, Shaji Kumar, MD57, Katja Weisel, MD58, Leo Rasche Jr, MD59, Yi Lin Jr, MD, PhD60, Lisa B Leypoldt, MD61
1 Mayo Clinic, Rochester, United States, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
2 Mayo Clinic, Rochester, United States, University Hospital Würzburg, Würzburg, Germany
3 University Hospital of Leipzig, Leipzig, Germany
4 Mayo Clinic, Jacksonville, Florida, United States
5 Mayo Clinic, Phoenix, Arizona, United States
6 Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
7 Faculty of Medicine and University Hospital Cologne University of Cologne, Cologne, Germany
8 University Hospital of Dresden, Dresden, Germany
9 LMU University Hospital, LMU Munich, Munich, Germany
10 University Hospital of Leipzig, Leipzig, Germany
11 Klinikum Chemnitz, Chemnitz, Germany
12 Klinikum Chemnitz, Chemnitz, Germany
13 University Hospital Mainz, Mainz, Germany
14 University Hospital Essen, Essen, Germany
15 University Hospital Essen, Essen, Germany
16 University Hospital Muenster, Münster, Germany
17 University Hospital Muenster, Münster, Germany
18 University Hospital Goettingen, Göttingen, Germany
19 University Hospital Inselspital, Bern, Switzerland
20 Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria
21 Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria, syndena GmbH, connect to cure, Innsbruck, Austria
22 Paracelsus Medical University, Salzburg, Austria
23 Paracelsus Medical University, Salzburg, Austria
24 Johannes Kepler University Linz, Linz, Austria, Ordensklinikum Linz, Linz, Austria
25 Universitätsspital Basel, Basel, Switzerland
26 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
27 Mayo Clinic, Rochester, United States
28 Mayo Clinic, Rochester, United States
29 Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
30 Charité - University Medicine Berlin, Berlin, Germany
31 Charité - University Medicine Berlin, Berlin, Germany
32 Charité - University Medicine Berlin, Berlin, Germany
33 University Medical Center Schleswig-Holstein – Campus Lübeck, Lübeck, Germany
34 Hannover Medical School, Hannover, Germany
35 Kantonsspital St. Gallen, St. Gallen, Switzerland
36 Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
37 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
38 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
39 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
40 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
41 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
42 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
43 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
44 University Hospital Würzburg, Würzburg, Germany
45 University Hospital Würzburg, Würzburg, Germany
46 University Hospital Würzburg, Würzburg, Germany
47 University Hospital Würzburg, Würzburg, Germany
48 LMU University Hospital, LMU Munich, Munich, Germany
49 LMU University Hospital, LMU Munich, Munich, Germany
50 Faculty of Medicine and University Hospital Cologne University of Cologne, Cologne, Germany
51 Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
52 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
53 University Hospital Würzburg, Würzburg, Germany
54 Memorial Sloan Kettering Cancer Center, New York, New York, United States, University Hospital of Leipzig, Leipzig, Germany
55 Mayo Clinic, Rochester, United States
56 Mayo Clinic, Rochester, United States
57 Mayo Clinic, Rochester, United States
58 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
59 University Hospital Würzburg, Würzburg, Germany
60 Mayo Clinic, Rochester, United States
61 University Medical Center Hamburg-Eppendorf, Hamburg, Germany

BCMA-directed treatments (BCMA-Tx) have improved outcomes of relapsed/refractory multiple myeloma (RRMM), but post-BCMA-Tx relapse represents an unmet need. Real-world data on BCMA-after-BCMA sequencing of the approved modalities CAR T cells, bispecific antibodies (bsAb), and antibody drug conjugate (ADC) remain limited. We investigated the outcomes of all possible BCMA-after-BCMA treatment strategies. Primary objective was PFS of the 2nd BCMA-Tx.

RRMM patients (pt) receiving ≥2 BCMA-Tx were retrospectively included. Intervening lines were allowed. Characteristics were summarized descriptively; PFS and OS were estimated by Kaplan-Meier (KM) with log-rank tests or Benjamini-Hochberg-adjusted (BH) log-rank tests and multivariable (age, pLOT, high-risk cytogenetics [HRCA by R-ISS] and EMD); median follow-up (mFU) by reverse KM.

220 pt from 22 centers from USA, Germany, Austria and Switzerland were included. At 2nd BCMA-Tx, median age was 65 years (range 32-86), with 7 (2-15) median prior lines (pLOT). HRCA according to R-ISS were present in 70/192 (36%) evaluable (ev.) pt, extraosseous EMD in 66/214 (31%). CAR T was the most frequent 1st BCMA-Tx (n=134, 61%), followed by ADC (58, 26%) and bsAb (28, 13%). Pt had a median of 1 (0-9) intervening line and 5.7 months (mo, 0-49.5) between progression on 1st BCMA-Tx to start of 2nd BCMA-Tx. BsAb were the most frequent 2nd BCMA-Tx (126, 57%), followed by CAR T (83, 38%) and ADC (11, 5%). The five most frequent sequences were CAR T→bsAb (96, 44%), CAR T→CAR T (ide cel→cilta cel, 32, 15%), ADC→bsAb (30, 14%), ADC→CAR T (28, 13%) and bsAb→CAR T (23, 10%). No pt received bsAb→bsAb or ADC→ADC. Overall response rate to 2nd BCMA-Tx was 69% (135/197 ev. pt), and 58% achieved ≥ VGPR.

With a mFU of 21 mo (95% CI: 16 to 27), the median (m)PFS for 2nd BCMA-Tx of all pt was 11 mo (CI: 7.8, 16). 2nd BCMA CAR T yielded a numerically superior mPFS of 22 mo (95% CI: 12 to not reached [NR]) compared to 5.4 mo for bsAb (95% CI: 3.4 to 14) and 2.3 mo for ADC (95% CI: 1.4 to NR) (log-rank p=0.004). With regard to how the 1st BCMA-Tx influences CAR T as 2nd BCMA-Tx, most favorable outcomes were seen with CAR T→CAR T (mPFS NR, 95% CI: 22 to NR; mFU 13 mo, 95% CI: 11 to 25) and ADC→CAR T (mPFS 28 mo, 95% CI: 15 to NR; mFU: 25 mo, 95% CI: 16 to NR) compared to bsAb→CAR T, which showed diminished survival (n=23; mPFS 6.5 mo, 95% CI: 2.3 to NR; mFU 27 mo, 95% CI: 5.1 to NR) (BH p<0.001, BH p=0.009). For pt relapsing after CAR T, 2nd CAR T was superior to bsAb (mPFS NR vs 5.4 mo; BH-p=0.001). In secondary adjusted Cox, compared to CAR T→bsAb as a reference, CAR T→CAR T (HR 0.23, 95% CI: 0.11 to 0.51, p<0.001) and ADC→CAR T (HR 0.48, 95% CI: 0.26 to 0.89, p=0.019) showed superior PFS, while no significant PFS differences were noted for the other cohorts.

Median intervening time between progression on the 1st BCMA-Tx and start of the 2nd BCMA-Tx differed numerically across cohorts (CAR T→bsAb: 2.7 mo; bsAb→CAR T: 7.1 mo; CAR T→CAR T: 8.5 mo; ADC→bsAb 8.0 mo; ADC→CAR T: 9.6 mo). In exploratory analysis, 2nd BCMA-Tx was not affected by this intervening time between progress on the 1st BCMA-Tx and start of the 2nd BCMA-Tx (<6 vs. >6 mo; log-rank p=0.983) or intervening talquetamab (log-rank p=0.971; bridging excluded). Durable response to the 1?? BCMA-Tx is associated with longer PFS of the 2n? BCMA-Tx with 5.1 (95% CI: 2.6 to 11), 9.8 (95% CI: 5.2, 25) and 22 mo (95% CI: 15 to NR) for 1st BCMA-Tx PFS <6 mo, 6 to <12 mo and >= 12 mo (log-rank p<0.001).

After 2nd BCMA-Tx, prolonged neutropenia, infections, CRS, and ICANS (any grade) occurred in 30%, 48% (grade ≥3 27%), 50%, and 2% of evaluable patients, respectively; non-relapse mortality among pt, who died, was 20% (16/80 evaluable pts).

With a mFU of 22 mo (95% CI: 19 to 29), mOS after 2nd BCMA-Tx was 29 mo (95% CI: 24, 39). mOS for 2nd BCMA-Tx showed no significant differences across cohorts (BH p=0.146), but in direct comparison CAR T→CAR T yielded in superior OS compared to CAR T→bsAb (BH p=0.0428).

Repeated BCMA-Tx yields high response rates with manageable toxicity, but PFS differs by sequence: CAR T→CAR T provides superior PFS on 2nd BCMA-Tx compared to CAR T→bsAb. ADC→CAR T was less detrimental than bsAb→CAR T and not inferior to CAR T→CAR T. With regards to a limited number of pts, CAR T→CAR T with product switching from ide-cel to cilta-cel achieved favorable outcomes. These data support CAR T before bsAb and highlight CAR T→bsAb as an unmet need.

Christoph Schaefers, MD: Abbvie, Astra Zeneca, GSK, Janssen-Cilag, Sanofi, Takeda - Honoraria; Abbvie, Astra Zeneca, GSK, Janssen-Cilag, Sanofi, Takeda - Honoraria; Astra Zeneca, GSK, Janssen-Cilag, Menarini Stemline, oncopeptides, Pfizer, Regeneron - Consultancy (Includes expert testimony); Astra Zeneca, GSK, Janssen-Cilag, Menarini Stemline, oncopeptides, Pfizer, Regeneron - Consultancy (Includes expert testimony)